Abgrall S, Ingle SM, May MT, Costagliola D, Mercie P, Cavassini M, et al. Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009. AIDS. 13 mars 2013;27(5):803‑13. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/23719350
Antiretroviral Therapy Cohort Collaboration (ART-CC). Influence of geographical origin and ethnicity on mortality in patients on antiretroviral therapy in Canada, Europe, and the United States. Clin Infect Dis. 15 juin 2013;56(12):1800‑9. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/23457077
Antiretroviral Therapy Cohort Collaboration (ART-CC), Shepherd BE, Jenkins CA, Parrish DD, Glass TR, Cescon A, et al. Higher rates of AIDS during the first year of antiretroviral therapy among migrants: the importance of tuberculosis. AIDS. 15 mai 2013;27(8):1321‑9. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/23925379
Hleyhel M, Belot A, Bouvier AM, Tattevin P, Pacanowski J, Genet P, et al. Risk of AIDS-defining cancers among HIV-1-infected patients in France between 1992 and 2009: results from the FHDH-ANRS CO4 cohort. Clin Infect Dis. 1 déc 2013;57(11):1638‑47. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/23899679
Huang X, Lodi S, Fox Z, Li W, Phillips A, Porter K, et al. Rate of CD4 decline and HIV-RNA change following HIV seroconversion in men who have sex with men: a comparison between the Beijing PRIMO and CASCADE cohorts. J Acquir Immune Defic Syndr. 1 avr 2013;62(4):441‑6. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/23221982
Kaulich-Bartz J, Dam W, May MT, Lederberger B, Widmer U, Phillips AN, et al. Insurability of HIV-positive people treated with antiretroviral therapy in Europe: collaborative analysis of HIV cohort studies. AIDS. 19 juin 2013;27(10):1641‑55. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/23449349
Lacombe J-M, Boue F, Grabar S, Viget N, Gazaignes S, Lascaux-Cametz A-S, et al. Risk of Kaposi sarcoma during the first months on combination antiretroviral therapy. AIDS. 20 févr 2013;27(4):635‑43. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/23196937
Lodi S, del Amo J, d’Arminio Monforte A, Abgrall S, Sabin C, Morrison C, et al. Risk of tuberculosis following HIV seroconversion in high-income countries. Thorax. mars 2013;68(3):207‑13. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/23117980
Lodi S, Fisher M, Phillips A, De Luca A, Ghosn J, Malyuta R, et al. Symptomatic illness and low CD4 cell count at HIV seroconversion as markers of severe primary HIV infection. PLoS One. 14 nov 2013;8(11):e78642. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/24244330
Madec Y, Boufassa F, Porter K, Prins M, Sabin C, d’Arminio Monforte A, et al. Natural history of HIV-control since seroconversion. AIDS. 24 sept 2013;27(15):2451‑60. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/23912979
Mocroft A, Furrer HJ, Miro JM, Reiss P, Mussini C, Kirk O, et al. The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era. Clin Infect Dis. 1 oct 2013;57(7):1038‑47. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/23921881
Mocroft A, Lundgren JD, Sabin ML, Monforte A d’Arminio, Brockmeyer N, Casabona J, et al. Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med. 3 oct 2013;10(9):e1001510. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/24137103
Montlahuc C, Guiguet M, Abgrall S, Daneluzzi V, de Salvador F, Launay O, et al. Impact of late presentation on the risk of death among HIV-infected people in France (2003-2009). J Acquir Immune Defic Syndr. 1 oct 2013;64(2):197‑203. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/24047970
Pursuing Later Treatment Option II (PLATO II) Project Team of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE), Costagliola D, Ledergerber B, Torti C, van Sighem A, Podzamczer D, et al. Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes. J Infect Dis. 1 mars 2013;207(5):759‑67. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/23225900
Sáez-Cirión A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. mars 2013;9(3):e1003211. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/23516360
van der Helm J, Geskus R, Sabin C, Meyer L, Del Amo J, Chêne G, et al. Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997. Gastroenterology. avr 2013;144(4):751-760.e2. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/23266560
